RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Alimera Sciences Stock

Alimera Sciences Net Income 2024

Alimera Sciences Net Income

-7.03 M USD

Ticker

ALIM

ISIN

US0162592028

WKN

A2PVHE

In 2024, Alimera Sciences's profit amounted to -7.03 M USD, a -67.15% increase from the -21.39 M USD profit recorded in the previous year.

The Alimera Sciences Net Income history

YEARNET INCOME (undefined USD)
2029e112.6
2028e86.53
2027e56.02
2026e23.85
2025e10.54
2024e-7.03
2023-21.39
2022-18.11
2021-4.37
2020-5.34
2019-10.44
201821.95
2017-22
2016-33.17
2015-30.65
2014-36.66
2013-51.18
2012-19.75
2011-22.52
2010-16.96
2009-52.42
2008-68.76
2007-10.64
2006-16.76
2005-15.35
2004-7.11

Alimera Sciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Alimera Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Alimera Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Alimera Sciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Alimera Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Alimera Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Alimera Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Alimera Sciences’s growth potential.

Alimera Sciences Revenue, EBIT and net profit per share

DateAlimera Sciences RevenueAlimera Sciences EBITAlimera Sciences Net Income
2029e278.83 M undefined0 undefined112.6 M undefined
2028e234.04 M undefined102.83 M undefined86.53 M undefined
2027e195.32 M undefined72.89 M undefined56.02 M undefined
2026e138.63 M undefined33.41 M undefined23.85 M undefined
2025e123.51 M undefined19.71 M undefined10.54 M undefined
2024e108.13 M undefined5.06 M undefined-7.03 M undefined
202380.75 M undefined-1.93 M undefined-21.39 M undefined
202254.13 M undefined-11.64 M undefined-18.11 M undefined
202159.03 M undefined-200,000 undefined-4.37 M undefined
202050.82 M undefined-500,000 undefined-5.34 M undefined
201953.94 M undefined-5.27 M undefined-10.44 M undefined
201846.6 M undefined-9.67 M undefined21.95 M undefined
201735.91 M undefined-16.45 M undefined-22 M undefined
201634.33 M undefined-27.85 M undefined-33.17 M undefined
201522.44 M undefined-39 M undefined-30.65 M undefined
20148.42 M undefined-32.95 M undefined-36.66 M undefined
20131.87 M undefined-34.41 M undefined-51.18 M undefined
20120 undefined-22.04 M undefined-19.75 M undefined
20110 undefined-21.41 M undefined-22.52 M undefined
20100 undefined-22.07 M undefined-16.96 M undefined
20090 undefined-19.22 M undefined-52.42 M undefined
20080 undefined-50.08 M undefined-68.76 M undefined
20070 undefined-12.52 M undefined-10.64 M undefined
20060 undefined-10.38 M undefined-16.76 M undefined
20050 undefined-6.08 M undefined-15.35 M undefined
20040 undefined-3.82 M undefined-7.11 M undefined

Alimera Sciences stock margins

The Alimera Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Alimera Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Alimera Sciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Alimera Sciences's sales revenue. A higher gross margin percentage indicates that the Alimera Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Alimera Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Alimera Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Alimera Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Alimera Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Alimera Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Alimera Sciences Margin History

Alimera Sciences Gross marginAlimera Sciences Profit marginAlimera Sciences EBIT marginAlimera Sciences Profit margin
2029e86.58 %0 %40.38 %
2028e86.58 %43.94 %36.97 %
2027e86.58 %37.32 %28.68 %
2026e86.58 %24.1 %17.2 %
2025e86.58 %15.95 %8.53 %
2024e86.58 %4.68 %-6.5 %
202386.58 %-2.39 %-26.49 %
202285.26 %-21.5 %-33.46 %
202188.09 %-0.34 %-7.4 %
202086.34 %-0.98 %-10.51 %
201987.73 %-9.77 %-19.35 %
201890.75 %-20.75 %47.1 %
201790.42 %-45.81 %-61.26 %
201693.18 %-81.12 %-96.62 %
201592.16 %-173.8 %-136.59 %
201482.9 %-391.33 %-435.39 %
20130.53 %-1,840.11 %-2,736.9 %
201286.58 %0 %0 %
201186.58 %0 %0 %
201086.58 %0 %0 %
200986.58 %0 %0 %
200886.58 %0 %0 %
200786.58 %0 %0 %
200686.58 %0 %0 %
200586.58 %0 %0 %
200486.58 %0 %0 %

Alimera Sciences Aktienanalyse

What does Alimera Sciences do?

Alimera Sciences Inc. is a leading global company specializing in the development of pharmaceutical products for eye diseases. The company was founded in 2003 in Atlanta, Georgia, USA and has since made remarkable progress in developing innovative clinical solutions. Business model: Alimera Sciences Inc. strives to utilize the latest technologies and methods in ophthalmology to improve the quality of life for patients with eye diseases. The company works closely with leading research institutions to incorporate the latest scientific findings into its product development. Alimera Sciences has a wide range of research areas to develop innovative solutions for conditions such as diabetes-related macular degeneration, retinopathy, uveitis, and other eye diseases. The company also places great value on collaboration with the medical community and actively advocates for the improvement of patient care and the education of eye experts. Products: Alimera Sciences' products are specialized in the treatment of eye diseases and utilize various technologies to improve patients' quality of life. The flagship product of Alimera Sciences is Iluvien, an intravitreal implant for the treatment of chronic diabetic macular edema (DME). Iluvien is the only commercially available DME implant and offers a unique treatment option for patients who do not respond to standard treatments. In addition to Iluvien, Alimera Sciences also manufactures a range of other products, including Ozurdex, a steroid-containing intravitreal implant for the treatment of retinopathy and uveitis. Alimera Sciences also has an extensive portfolio of investigational drugs, many of which are in various stages of clinical development. History: Alimera Sciences was founded in 2003 by Daniel C. Myers and David R. Holland in Atlanta, Georgia. The company originally specialized in developing drugs for the treatment of lung diseases, but over the years, its focus shifted to ophthalmology. In 2011, the company received FDA approval for Iluvien, which was a significant milestone in the history of Alimera Sciences. Since then, the company has continuously expanded its presence in ophthalmology by increasing its research and development efforts and forming partnerships with key medical organizations and institutions. Today, Alimera Sciences is a leading provider of pharmaceutical solutions for eye diseases, focusing on the development of drugs to improve patients' quality of life and enhance medical care. Conclusion: Overall, Alimera Sciences is an innovative company specializing in the development of drugs for the treatment of eye diseases. In its 18 years of existence, the company has achieved an impressive success story and continues its efforts to attain a leading position in the ophthalmic industry. With insights and experience in medical history and the knowledge of important medical professionals, the company is prepared to continuously meet the medical needs and expectations of patients with eye diseases. Alimera Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Alimera Sciences's Profit Margins

The profit margins of Alimera Sciences represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Alimera Sciences's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Alimera Sciences's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Alimera Sciences's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Alimera Sciences’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Alimera Sciences stock

How much profit has Alimera Sciences made this year?

Alimera Sciences has made -7.03 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -67.15% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Alimera Sciences publish its earnings?

Alimera Sciences publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Alimera Sciences?

The profits of Alimera Sciences are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Alimera Sciences?

You can learn more about the earnings of Alimera Sciences by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Alimera Sciences pay?

Over the past 12 months, Alimera Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Alimera Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Alimera Sciences?

The current dividend yield of Alimera Sciences is .

When does Alimera Sciences pay dividends?

Alimera Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Alimera Sciences?

Alimera Sciences paid dividends every year for the past 0 years.

What is the dividend of Alimera Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Alimera Sciences located?

Alimera Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Alimera Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Alimera Sciences from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Alimera Sciences pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Alimera Sciences in the year 2023?

In the year 2023, Alimera Sciences distributed 0 USD as dividends.

In which currency does Alimera Sciences pay out the dividend?

The dividends of Alimera Sciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Alimera Sciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Alimera Sciences

Our stock analysis for Alimera Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alimera Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.